Moventig Grunenthal GmbH · Authorised · authorised 7 Dec 2014 · ATC A06AH03
Therapeutic indication (EMA)
Treatment of opioid-induced constipation (OIC) in adult patients who have had an inadequate response to laxative(s).
Active substance
Naloxegol
- US FDA 1
- EMA 1
- Health Canada 2
- US price lines 2
- NHS prices 2
- Safety 1
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| MOVANTIK | EQ 12.5MG BASE; EQ 25MG BASE | tablet · oral | AVERITAS | Prescription | 16 Sep 2014 |
EMA European Union — centrally authorised medicines
Canada Canada — marketed products (Health Canada)
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| US NADAC | MOVANTIK 12.5 MG TABLET | $14.59872 | per EA | 23 Sep 2026 |
| US NADAC | MOVANTIK 25 MG TABLET | $14.61317 | per EA | 23 Sep 2026 |
| NHS Drug Tariff | Naloxegol 12.5mg tablets | £55.20 | 30 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Naloxegol 25mg tablets | £55.20 | 30 tablet | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
Safety signals and safety-related labeling changes
- US FDA 13 Apr 2020 MOVANTIK — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Adverse Reactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.